Zacks.com featured highlights include United Natural Foods, Teladoc Health, Supernus and BRP

For Immediate Release

Chicago, IL – October 16, 2025 – Stocks in this week’s article are United Natural Foods UNFI, Teladoc Health TDOC, Supernus Pharmaceuticals SUPN and BRP Inc. DOOO.

Can 4 Relative Price Strength Stocks Defy Market Swings?

After a brief stumble triggered by renewed U.S.-China trade tensions, Wall Street found its footing once again. The market’s sharp selloff, fueled by tariff threats and restrictions on rare earth exports, was quickly followed by a broad rebound as conciliatory comments from both sides hinted at a possible dialogue ahead. Investors saw this as a sign that while the trade conflict remains heated, a full-blown escalation looks unlikely for now.

Major indexes stayed resilient, showing strong underlying momentum even amid policy uncertainty. That balance between volatility and optimism reflects a market still supported by easing monetary policy, solid earnings, and investor confidence in economic stability. In such conditions, relative price strength becomes a powerful approach — helping investors focus on stocks that continue to outperform despite turbulence, the true leaders likely to extend gains once calm returns.

At this stage, investors would be wise to consider stocks such as United Natural Foods, Teladoc Health, Supernus Pharmaceuticals and BRP Inc. based on their relative price strength.

Relative Price Strength Strategy

Investors generally gauge a stock’s potential returns by examining earnings growth and valuation multiples. At the same time, it’s essential to measure the performance of such a stock relative to its industry, peers, or an appropriate benchmark.

If you see that a stock is underperforming on fundamental factors, it would be prudent to move on and find a better alternative. However, those outperforming their respective sectors in terms of price should be selected because they stand a better chance of providing considerable returns.

Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals, indicate room for growth and are the best ways to go about this strategy.

Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.

Here are four of the seven stocks that made it through the screen:

United Natural Foods: It is the leading distributor of natural, organic and specialty food and non-food products in the United States and Canada. The Zacks Consensus Estimate for fiscal 2026 earnings of United Natural Foods indicates 167.6% growth. Headquartered in Providence, RI, UNFI has a VGM Score of A.

The firm has a market capitalization of $2.5 billion. Notably, over the past 60 days, the Zacks Consensus Estimate for United Natural Foods’ fiscal 2026 earnings has moved up 24.2%. UNFI’s shares have gone up 102% in a year.

Teladoc Health: Based in Purchase, NY, it provides virtual access to high-quality care and expertise with a portfolio of services and solutions. Teladoc Health’s expected EPS growth rate for three to five years is currently 48.4%, which compares favorably with the industry's growth rate of 15.1%. The company has a VGM Score of A.

The Zacks Consensus Estimate for Teladoc Health’s 2025 earnings per share indicates 80.1% year-over-year growth. It beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, with the average being 18.3%. TDOC shares have lost 6.1% in a year.

Supernus Pharmaceuticals: Based in Rockville, MD, Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders, including epilepsy, migraine, ADHD, and Parkinson’s, with a diverse, established product portfolio. SUPN has a market capitalization of $2.7 billion. It has a VGM Score of B.

Notably, over the past 60 days, the Zacks Consensus Estimate for Supernus Pharmaceuticals’ 2025 earnings has moved up 9.8%. It beat the Zacks Consensus Estimate for earnings in each of the last four quarters, with the average being 80%. SUPN shares have soared 46.8% in a year.

BRP Inc.: Based in Canada, BRP is a global leader in powersports, designing and manufacturing ATVs, SSVs, three-wheelers, snowmobiles, and personal watercraft under brands like Can-Am, Ski-Doo, Lynx, and Sea-Doo. BRP has a market capitalization of $4.8 billion. It has a VGM Score of A.

Notably, over the past 60 days, the Zacks Consensus Estimate for BRP’s fiscal 2026 earnings has moved up 26.2%. It beat the Zacks Consensus Estimate for earnings in each of the last four quarters, with the average being 49.5%. BRP shares have gained 19.9% in a year.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2769600/can-4-relative-price-strength-stocks-defy-market-swings

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: [email protected]

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research